Bio-Techne Corp TECH:NASDAQ

Last Price$210.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/17/19

Today's Change-0.25(0.12%)
Bid (Size)$210.02 (4)
Ask (Size)$210.28 (12)
Day Low / High$209.71 - 212.29
Volume81.0 K

View Biotechnology IndustryPeer Comparison as of 07/17/2019


Bio-Techne Corp ( NASDAQ )

Price: $210.03
Change: -0.25 (0.12%)
Volume: 81.0 K
4:00PM ET 7/17/2019

Neurocrine Biosciences Inc ( NASDAQ )

Price: $88.12
Change: +1.03 (1.18%)
Volume: 497.9 K
4:00PM ET 7/17/2019

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $72.68
Change: -1.56 (2.10%)
Volume: 966.3 K
4:00PM ET 7/17/2019

bluebird bio Inc ( NASDAQ )

Price: $139.45
Change: +5.79 (4.33%)
Volume: 651.8 K
4:00PM ET 7/17/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Read more news Recent News

Bio-Techne Launches Cartridge for Use in Medical Testing
10:10AM ET 7/17/2019 MT Newswires

Bio-Techne Corp (TECH) said Wednesday that it has released a new cartridge format for the ProteinSimple-branded Ella automated immunoassay platform used to...

--Analyst Actions: Janney Upgrades Bio-Techne to Buy From Neutral, Boosts Price Target To $270 From $200
7:36AM ET 7/02/2019 MT Newswires

Price: 209.26, Change: +0.77, Percent Change: +0.37 ...

Bio-Techne's Prostate Text Receives FDA's Breakthrough Device Designation
2:03PM ET 6/17/2019 MT Newswires

Bio-Techne Corp. (TECH) said Monday that the US Food and Drug Administration has granted breakthrough device designation to its ExoDx Prostate IntelliScore...

Insider Trends: Bio-Techne Insider Extends 90-Day Selling Trend
4:15PM ET 6/14/2019 MT Newswires

Norman David Eansor, SVP - Novus Biologicals, reported a sale of 3,117 shares in Bio-Techne (TECH) on Jun 12, 2019, for $670,155. The sale of shares of...

View all Commentary and Analysis

Bio-Techne (TECH) Investor Presentation - Slideshow
3:44PM ET 6/12/2019 Seeking Alpha

Daily Insider Ratings Round Up 5/29/19
1:20PM ET 5/31/2019 Seeking Alpha

Retail On Display (Stocks To Watch Podcast)
7:35AM ET 5/19/2019 Seeking Alpha

Stocks To Watch: Retail On Display
7:41AM ET 5/18/2019 Seeking Alpha

Company Profile

Business DescriptionBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN. View company web site for more details
Address614 McKinley Place NE
Minneapolis, Minnesota 55413-2610
Number of Employees1,943
Recent SEC Filing07/12/20194
President, Chief Executive Officer & DirectorCharles R. Kummeth
CFO & Principal Accounting OfficerJames T. Hippel
Chief Medical OfficerRobert Monroe
Secretary, Senior Vice President & General CounselBrenda S. Furlow

Company Highlights

Price Open$210.20
Previous Close$210.03
52 Week Range$132.75 - 217.16
Market Capitalization$8.0 B
Shares Outstanding37.9 M
SectorHealth Technology
Current Dividend / Yield$0.32 / 0.61%
Dividend Ex-Date05/09/2019
Dividend Pay-Date05/24/2019
Dividend Yield 5 Year AverageN/A
Next Earnings Announcement08/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings67.32
Earnings per Share$3.16
Beta vs. S&P 500N/A
Revenue$643.0 M
Net Profit Margin17.14%
Return on Equity10.87%

Analyst Ratings as of 07/05/2019

Consensus RecommendationConsensus Icon
Powered by Factset